Clinical Trial Update: NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) [Phase 3]

View source ↗

Summary

Clinical trial update for NeoFOL-R, a Phase 3 study comparing perioperative versus adjuvant FOLFIRINOX in resectable pancreatic cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Resectable Pancreatic Cancer, Neoadjuvant Chemotherapy | Phase 3 | Status: RECRUITING